April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
January 2024 in “Wiadomości Lekarskie” Enhancing immune response can improve cancer treatment effectiveness.
1 citations
,
February 2023 in “Pediatric Dermatology” Early recognition of symptoms is crucial for treating IPEX syndrome with a stem cell transplant.
7 citations
,
March 2018 in “Journal of The American Academy of Dermatology” Skin changes like hair loss, white patches, and nail changes are common in children after bone marrow transplants, often linked to chronic rejection.
November 2024 in “Rheumatology Advances in Practice” Early recognition and treatment of SLE can improve outcomes in patients with complex symptoms.
November 2007 in “Pediatrics in review” A boy with long QT syndrome was treated successfully, highlighting the need for careful evaluation of chest pain in children for heart conditions like LQTS.
7 citations
,
August 2020 in “Scientifica” Most HIV-positive patients had skin problems, and conditions like oral thrush and boils were linked to weaker immune systems.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Montelukast is linked to increased risks of suicidal thoughts and depression.
May 2022 in “The FASEB Journal” Finasteride may help treat Neutrophil Actin Dysfunction by reducing LSP1 gene activity.
April 2023 in “Journal of Investigative Dermatology” Using DNase enzymes to break down harmful NETs could be a new treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Scarred skin in lichen planopilaris loses immune cells due to a decrease in a specific protein in skin cells.
The treatment showed limited success in repigmenting hair for vitiligo-associated leukotrichia.
September 1997 in “Journal of the European Academy of Dermatology and Venereology” People with acne have more CD4+ immune cells in their skin than healthy people.
January 2026 in “JCEM Case Reports” A woman with hypothyroidism developed an allergy to IV levothyroxine after being resistant to oral forms.
January 1994 in “Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics” Both VEPA and ML-Y1 treatments are not effective enough for elderly non-Hodgkin's lymphoma patients.
February 2008 in “Vlaams dierengeneeskundig tijdschrift” A cat's hair loss was linked to a severe pancreatic cancer.
4 citations
,
April 2007 in “Journal of Pediatric Gastroenterology and Nutrition” A liver transplant patient with APECED had a rare VZV recurrence and pneumonia, treated successfully, but later died from other infections.
11 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
12 citations
,
June 2020 in “Lupus” Early treatment with the right dose of stem cells can reduce lupus symptoms.
52 citations
,
September 2021 in “Kidney International” COVID-19 vaccination may trigger lupus in some people.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
July 2025 in “Clinical Dermatology Review” Azathioprine can cause unexpected hair loss and severe bone marrow issues, so careful monitoring is needed.
February 2024 in “Future science OA” Loss of the Y chromosome and UTY gene activity increases cancer risk in men.
January 1991 in “Linchuang pifuke zazhi”
40 citations
,
August 2010 in “Archives of dermatology” A 5-year-old boy's skin condition improved with systemic valganciclovir after a cardiac transplant and immunosuppressive therapy.
January 2023 in “National journal of physiology, pharmacy and pharmacology” Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
February 1977 in “Archives of Dermatology” Topical mitotic blocking agents like colchicine can be dangerous and potentially fatal, and hair loss from rapid weight loss is due to low protein, not the speed of weight loss.